AIDS buyers clubs
Should be notified about the results of FDA's analysis of underground versions of Roche's Hivid (ddC), says Direct Action for Treatment Access (DATA), a California-based advocacy group. FDA said Feb. 6 that counterfeit ddC showed "potentially serious variations in product potency and quality" and told the inspected clubs to stop shipping the drug immediately. DATA says that FDA should notify uninspected buyers clubs and the general public of the potential dangers of variations in ddC potency.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth